The ability of phytocannabinoids to target and modulate the activity of the endocannabinoid system is at the core of the therapeutic potential of cannabinoid-based medicines.

 Moreover, the endocannabinoid system plays a modulatory role in virtually all pathological conditions, with distinct degrees of impact for the outcome of the disease. Therefore, the therapeutic window of cannabinoid-based medicines embraces an exceptionally broad range of diseases and pathological conditions, something really unique in biomedicine.

Extensive preclinical research has characterized the biological properties of the main cannabinoids, which include:

Analgesic, anti-inflammatory, anticonvulsant, hypnogenic, antispastic, antitumoral, neuroprotective, orexigenic, anxiolytic, antidepressant, antioxidant, antipsychotic, antiemetic, etc.

Accordingly, increasing clinical evidence supports a therapeutic potential of cannabinoid-based medicines in a broad range of pathological conditions, including:

Palliative care, chronic pain, sleep disorders, anxiety, cachexia, epilepsy, autism spectrum disorders, movement disorders, neurodegenerative diseases, psychiatric disorders, skin diseases, cancer, metabolic disorders, inflammatory bowel disease, autoimmune disorders, gynecological conditions, migraine, fibromyalgia, addiction, etc.